This Quantitative Pharmacology Assay (QPA) Core (C) supports the program entitled "Developmental and Translational Pharmacology of Pediatric Antimicrobial Therapy", submitted as an application responsive to RFA-HD-10-026: Specialized Center in Research in Pediatric Developmental Pharmacology (RPDP) Program (U54). The overall theme of the proposed program at UC San Diego is to bring together non-clinical and clinical experts in the fields of developmental physiology, pharmacology, and infectious diseases and conduct translational research to advance the field of pediatric developmental pharmacology. The QPA Core will provide timely, accurate and cost effective quantitative assays in support of the UC San Diego Research in Pediatric Development Pharmacology (RPDP) Center Projects and Pilot Projects. It will adopt published analytical methods and develop de-novo approaches to measure drugs, their metabolites and as antimicrobial peptides using small sample volumes appropriate for pediatric populations. These assay will cover various matrices including, plasma, intracellular, urine and tissue. Various methodologies are available including HPLC with UV detection, RIA, LC/MS/MS, and GC/MS. The QPA Core maintains medical licensure under CLIA and participates in NIAID's Clinical Pharmacology Quality Assurance program. The laboratory will work closely with the PM Core to determine assay sensitivity requirements so the most cost effective method can be used. The QPA Core will also collaborate with the Training &Outreach Core to provide assay methodology training opportunities for students, residents and fellows.
Development of sensitive, accurate and cost effective quantitative assays is an essential capability for clinical and translational pharmacology research. Use of small sample volumes and attention to metabolites and atypical matrices can maximize the knowledge generated from pediatric pharmacology studies.
|Lam, Lisa H; Capparelli, Edmund V; Kurzrock, Razelle (2016) Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol 78:427-32|
|Le, J; Dam, Q; Schweizer, M et al. (2016) Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37. Eur J Clin Microbiol Infect Dis 35:1441-7|
|Martovetsky, Gleb; Bush, Kevin T; Nigam, Sanjay K (2016) Kidney versus Liver Specification of SLC and ABC Drug Transporters, Tight Junction Molecules, and Biomarkers. Drug Metab Dispos 44:1050-60|
|Shoji, Kensuke; Bradley, John S; Reed, Michael D et al. (2016) Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms. Antimicrob Agents Chemother 60:2150-6|
|Sakoulas, George; Olson, Joshua; Yim, Juwon et al. (2016) Cefazolin and Ertapenem: A Synergistic Combination Used to Clear Persistent Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother :|
|Lin, Leo; Kim, Janie; Chen, Hope et al. (2016) Component Analysis of Multipurpose Contact Lens Solutions To Enhance Activity against Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother 60:4259-63|
|Hollands, Andrew; Corriden, Ross; Gysler, Gabriela et al. (2016) Natural Product Anacardic Acid from Cashew Nut Shells Stimulates Neutrophil Extracellular Trap Production and Bactericidal Activity. J Biol Chem 291:13964-73|
|Cole, Jason N; Nizet, Victor (2016) Bacterial Evasion of Host Antimicrobial Peptide Defenses. Microbiol Spectr 4:|
|Kumaraswamy, Monika; Lin, Leo; Olson, Joshua et al. (2016) Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia. J Antimicrob Chemother 71:1264-9|
|Bosi, Emanuele; Monk, Jonathan M; Aziz, Ramy K et al. (2016) Comparative genome-scale modelling of Staphylococcus aureus strains identifies strain-specific metabolic capabilities linked to pathogenicity. Proc Natl Acad Sci U S A 113:E3801-9|
Showing the most recent 10 out of 61 publications